Targeted therapy reversing malignant biliary obstruction in advanced hepatocellular carcinoma: A mechanistic clinical observation challenging the bilirubin contraindication threshold for lenvatinib

Introduction: Current prescribing guidelines restrict Lenvatinib to patients with serum bilirubin ≤3 mg/dL, a threshold derived from pharmacokinetic data in hepatocellular dysfunction. This restriction does not distinguish between hepatocellular decompensation and tumour-mediated biliary obstruction - a mechanistically distinct entity in which hepatic synthetic function and drug metabolism may remain fully preserved. No prospective study has evaluated the safety or feasibility of Lenvatinib in HCC-mediated obstructive hyperbilirubinemia.
Aims & Methods: We report a proof-of-concept clinical observation of a 65-year-old male with HCV-related cirrhosis and advanced HCC (BCLC Stage C, Child-Pugh A) presenting with severe obstructive jaundice caused by tumour infiltration of the biliary hilum (MRCP-confirmed; peak total bilirubin 24.5 mg/dL). Percutaneous transhepatic drainage (PTD) was placed but confirmed non-functional throughout. Given preserved hepatic synthetic function (Child-Pugh A, INR 1.36, albumin 3.1 g/dL) and CT-confirmed mechanical ductal obstruction as the sole mechanism of hyperbilirubinemia, Lenvatinib 10 mg once daily was initiated at total bilirubin 11.6 mg/dL -3.9-fold above the approved threshold - following full informed consent.
Results: Over 25 days with the PTD confirmed non-functional throughout, total bilirubin declined 72.4% (11.6→3.2 mg/dL) and direct bilirubin declined 68.2% (7.23→2.3 mg/dL). Transaminases normalised in parallel (ALT: 123→71 U/L; AST: 84→56 U/L). Follow-up CT (Day 29) confirmed resolution of marked intrahepatic biliary duct dilatation (IHBD) to minimal residual dilatation, providing radiological corroboration of biliary decompression. No grade ≥2 adverse events, hepatotoxicity, or dose modification occurred. The non-functionality of the PTD throughout excludes mechanical drainage as a confounding explanation and implicates Lenvatinib-induced tumour regression as the mechanism.
Conclusion: This observation provides first clinical evidence that HCC-mediated obstructive hyperbilirubinemia is mechanistically distinct from hepatocellular dysfunction, and that the universal bilirubin ≤3 mg/dL contraindication may be inappropriately applied to Child-Pugh A patients with tumour-mediated biliary obstruction and intact drug metabolism. Lenvatinib may confer a dual benefit -anti-tumour efficacy and obstructive jaundice resolution - in this clinically identifiable subgroup. Prospective multi-centre evaluation with pharmacokinetic monitoring is warranted.